Term ended May 6, 2024 · High confidence
20-year base term ended May 6, 2024
USPTO later recorded it as expired for non-payment on Jun 9, 2025.
Held by Bioverativ Therapeutics Inc.
Filed Oct 31, 2014 as application 14/530,256 · Granted May 2, 2017
Base term, 20 years from filing
Today
Term ended May 6, 2024
2004
2026
Clock starts
May 6, 2004
May 6, 2004
Term ended
May 6, 2024
May 6, 2024
Granted
May 2, 2017
May 2, 2017
base term
after the term ends
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,381,408, US 7,820,162, to May 6, 2024. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
12
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 6, 2004, when application 10/841,250, the earliest non-provisional in its chain, was filed (this one was filed Oct 31, 2014) | May 6, 2024 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,381,408, US 7,820,162) | resolves to May 6, 2024, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 1 maintenance fees paid | term ended | High confidence |
| USPTO status record | Recorded as expired for non-payment on Jun 9, 2025, after the term ended | no change | High confidence |
| Computed term end | The steps above, in order | May 6, 2024 | High confidence |
This family
| US 7,404,956 | In force Jun 2028 | Jun 2028 |
| US 7,348,004 | In force Mar 2028 | Mar 2028 |
| Application PCT/US2006/000140 | PCT application no patent term | no patent term |
| US 7,862,820 | Term ended no later than Mar 2026 | no later than Mar 2026 |
| US 8,329,182 | Term ended no later than May 2024 | no later than May 2024 |
| US 8,932,830 | Term ended May 2024 | May 2024 |
| US 9,636,416 | this patent May 2024 | May 2024 |
| US 11,401,322 | Term ended May 2024 | May 2024 |
8 of 12 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 31, 2015 Reel 34870, frame 234 | Syntonix Pharmaceuticals, Inc. | Biogen Idec Hemophilia Inc. | Change of Name |
| Mar 16, 2015 Reel 35168, frame 825 | Peters, Robert T.; Mezo, Adam R.; Rivera, Daniel S.; Bitonti, Alan J.; Low, Susan C. | Syntonix Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Apr 30, 2015 Reel 35553, frame 325 | Biogen Idec Hemophilia Inc. | Biogen Hemophilia Inc. | Change of Name |
| Jul 2, 2015 Reel 36051, frame 773 | Biogen Hemophilia Inc. | Biogen Hemophilia Inc. | Change of Address |
| Feb 16, 2017 Reel 41735, frame 621 | Biogen Hemophilia Inc. | Bioverativ Therapeutics Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,381,408, US 7,820,162, ends no earlier than this term, so it caps nothing.
Citations
30
later US patents cite this one
That is top 25% of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.